AR073361A1 - Combinacion farmaceutica que comprende 3-(-3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico. uso - Google Patents

Combinacion farmaceutica que comprende 3-(-3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico. uso

Info

Publication number
AR073361A1
AR073361A1 ARP090103405A ARP090103405A AR073361A1 AR 073361 A1 AR073361 A1 AR 073361A1 AR P090103405 A ARP090103405 A AR P090103405A AR P090103405 A ARP090103405 A AR P090103405A AR 073361 A1 AR073361 A1 AR 073361A1
Authority
AR
Argentina
Prior art keywords
phenol
propyl
methyl
component
antiepileptico
Prior art date
Application number
ARP090103405A
Other languages
English (en)
Spanish (es)
Inventor
Klaus Schiene
Petra Bloms-Funke
Thomas Dr Christoph
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR073361A1 publication Critical patent/AR073361A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ARP090103405A 2008-09-05 2009-09-04 Combinacion farmaceutica que comprende 3-(-3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico. uso AR073361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05

Publications (1)

Publication Number Publication Date
AR073361A1 true AR073361A1 (es) 2010-11-03

Family

ID=40345058

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090103405A AR073361A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica que comprende 3-(-3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico. uso
ARP190102034A AR117613A2 (es) 2008-09-05 2019-07-19 Combinación farmacéutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190102034A AR117613A2 (es) 2008-09-05 2019-07-19 Combinación farmacéutica

Country Status (28)

Country Link
US (1) US20100063148A1 (enExample)
EP (2) EP2735338B1 (enExample)
JP (4) JP5731387B2 (enExample)
KR (3) KR101641519B1 (enExample)
CN (2) CN102159284B (enExample)
AR (2) AR073361A1 (enExample)
AU (3) AU2009289776A1 (enExample)
BR (1) BRPI0920521A2 (enExample)
CA (1) CA2735857C (enExample)
CL (1) CL2011000317A1 (enExample)
CO (1) CO6382142A2 (enExample)
CY (2) CY1115751T1 (enExample)
DK (2) DK2735338T3 (enExample)
EC (1) ECSP11010869A (enExample)
ES (2) ES2513394T3 (enExample)
HR (2) HRP20140663T1 (enExample)
HU (1) HUE043278T2 (enExample)
IL (3) IL211135A (enExample)
LT (1) LT2735338T (enExample)
MX (1) MX2011002339A (enExample)
PE (5) PE20142357A1 (enExample)
PL (2) PL2331210T3 (enExample)
PT (2) PT2331210E (enExample)
RU (2) RU2571501C2 (enExample)
SI (2) SI2331210T1 (enExample)
TR (1) TR201904388T4 (enExample)
WO (1) WO2010025931A2 (enExample)
ZA (1) ZA201101449B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
AU2007260207B2 (en) * 2006-06-15 2012-11-08 Ucb Pharma Gmbh Pharmaceutical composition with synergistic anticonvulsant effect
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
JP5731387B2 (ja) * 2008-09-05 2015-06-10 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬配合剤
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
PL2582366T3 (pl) 2010-06-15 2016-04-29 Gruenenthal Gmbh Kombinacja farmaceutyczna do leczenia bólu
WO2012003968A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
CN103002893B (zh) 2010-07-30 2017-05-10 东丽株式会社 神经障碍性疼痛的治疗药或预防药
BR112013022213A2 (pt) * 2011-03-04 2017-05-02 Gruenenthal Gmbh administração parenteral de tapentadol
US11413239B2 (en) * 2011-07-20 2022-08-16 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol for nasal administration
LT2736501T (lt) * 2011-07-29 2018-03-26 GrĆ¼nenthal GmbH 3-[(1s,2s)-3-(dimetilamino)-1-etil-2-metilpropil]fenolio intratekalinis arba epiduralinis skyrimas
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
EP2914243A1 (en) * 2012-11-01 2015-09-09 Torrent Pharmaceuticals Limited Pharmaceutical composition of tapentadol for parenteral administration
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
US20170174614A1 (en) 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
FI3800177T3 (fi) 2015-12-22 2025-04-29 Zogenix International Ltd Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
US11571397B2 (en) 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
CA3117868A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
EP1210118B1 (en) * 1999-08-20 2004-12-08 Ortho-McNeil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
US20060167032A1 (en) * 2002-01-16 2006-07-27 Galer Bradley S Pharmaceutical composition and method for treating disorders of the central nervous system
WO2003070237A1 (en) * 2002-02-22 2003-08-28 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
WO2007128412A1 (en) * 2006-04-28 2007-11-15 Grünenthal GmbH Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
DK2596784T3 (en) * 2007-11-23 2017-03-06 Gruenenthal Gmbh Tapentadol compositions
EP2250143B1 (en) * 2008-01-25 2016-04-20 XenoPort, Inc. Method for the enzymatic kinetic resolution of acyloxyalkyl thiocarbonates used for the synthesis of acyloxyalkyl carbamates
JP5731387B2 (ja) * 2008-09-05 2015-06-10 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬配合剤

Also Published As

Publication number Publication date
JP2012501986A (ja) 2012-01-26
TR201904388T4 (tr) 2019-05-21
WO2010025931A2 (en) 2010-03-11
CA2735857A1 (en) 2010-03-11
DK2735338T3 (en) 2019-04-23
HK1159011A1 (en) 2012-07-27
AU2016203053A1 (en) 2016-06-02
RU2011112444A (ru) 2012-10-10
SI2331210T1 (sl) 2014-10-30
HRP20190500T1 (hr) 2019-08-09
IL237392A0 (en) 2015-04-30
CN105520924B (zh) 2019-04-09
PE20190914A1 (es) 2019-06-26
AU2016203053B2 (en) 2018-01-25
BRPI0920521A2 (pt) 2018-01-16
AR117613A2 (es) 2021-08-18
IL237391A (en) 2017-12-31
HRP20140663T1 (hr) 2014-10-10
PL2735338T3 (pl) 2019-07-31
US20100063148A1 (en) 2010-03-11
CY1121492T1 (el) 2020-05-29
JP2017071636A (ja) 2017-04-13
KR20160086981A (ko) 2016-07-20
CN102159284B (zh) 2015-12-09
PE20142357A1 (es) 2015-02-04
RU2571501C2 (ru) 2015-12-20
JP2015096530A (ja) 2015-05-21
CY1115751T1 (el) 2017-01-25
IL237392B (en) 2019-08-29
CA2735857C (en) 2019-05-28
AU2018202879A1 (en) 2018-05-17
PE20142372A1 (es) 2015-02-04
PL2331210T3 (pl) 2014-12-31
CN102159284A (zh) 2011-08-17
KR101641519B1 (ko) 2016-07-21
PT2331210E (pt) 2014-08-25
PE20110291A1 (es) 2011-06-04
IL211135A0 (en) 2011-04-28
KR20110057144A (ko) 2011-05-31
PE20142371A1 (es) 2015-02-04
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
IL211135A (en) 2017-09-28
KR101730924B1 (ko) 2017-04-27
SI2735338T1 (sl) 2019-04-30
EP2735338A1 (en) 2014-05-28
CO6382142A2 (es) 2012-02-15
JP5731387B2 (ja) 2015-06-10
DK2331210T3 (da) 2014-08-11
KR20170048602A (ko) 2017-05-08
ES2513394T3 (es) 2014-10-27
ZA201101449B (en) 2011-10-26
HK1198145A1 (en) 2015-03-13
CN105520924A (zh) 2016-04-27
CL2011000317A1 (es) 2011-06-17
HUE043278T2 (hu) 2019-08-28
EP2735338B1 (en) 2019-02-06
MX2011002339A (es) 2011-04-04
JP2019131578A (ja) 2019-08-08
AU2009289776A1 (en) 2010-03-11
PT2735338T (pt) 2019-05-24
ECSP11010869A (es) 2011-04-29
WO2010025931A3 (en) 2010-06-17
EP2331210B1 (en) 2014-07-09
ES2719900T3 (es) 2019-07-16
AU2018202879B2 (en) 2020-03-12
EP2331210A2 (en) 2011-06-15
IL237391A0 (en) 2015-04-30
RU2674150C1 (ru) 2018-12-05

Similar Documents

Publication Publication Date Title
AR073361A1 (es) Combinacion farmaceutica que comprende 3-(-3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico. uso
ECSP19047259A (es) Combinación farmacéutica para el tratamiento del dolor
CL2012003009A1 (es) Acido3-(((3-butil-3-etil-(metiloxi)-1-1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,4benxotiazepin-8-il)-metil)-amino)-pentanodioco; composicion farmaceutica que lo comprende; y su uso en un tastorno metabolico. pct.
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CO6290631A2 (es) Composición oral que contiene amino ácidos y un agente blanqueador
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CL2011002255A1 (es) Compuestos derivados de 2-acetamino-5-aril-(1,2,4-triazolona o imidazolona), antagonista del receptor v1a y v2; composicion farmaceutica que los comprende; procedimiento de preparacion; y su uso en el tratamiento de insuficiencia cardiaca, hiponatremia hipervolemica y euvolemica, ascitis, ademas, entre otras.
CL2009000404A1 (es) Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras.
UY31922A (es) Compuestos
ECSP13013011A (es) Triazolopiridinas
CO6650348A2 (es) Triazolopiridinas sustituidas
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
AR052184A1 (es) Mezclas fungicidas
AR071533A1 (es) Microemulsion mejorada con un amplio rango de aplicacion
CL2009000084A1 (es) Compuestos derivados de sulfonamida sustituida, moduladores de receptores de bradiquinina; composicion farmaceutica que contiene a los compuestos; y uso en el tratamiento del dolor agudo, neuropatico o cronico, entre otros.
CL2009001240A1 (es) Compuestos derivados del acido l-glutamico y l-glutamina marcados con [f-18]; procedimiento de preparacion; composicion farmaceutica que comprende a los compuestos y su uso como agentes en el diagnostico de tumores.
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
CL2009000246A1 (es) Compuestos derivados de 1h-imidazo[4,5-b]piridin-2-ol; moduladores de la contraccion sarcomero; composicion farmaceutica que comprende; kit farmaceutico; y uso en el tratamiento de enfermedades neuromusculares, tales como atrofia, fatiga, claudicacion, en entre otras.
AR072263A1 (es) Compuestos pirido-pirimidina que inhiben mtor composiciones farmaceuticas que los comprenden procesos para su preparacion y su uso como un medicamento
AR077987A1 (es) Combinacion farmaceutica que comprende 6-dimetilaminometil-1-(3-metoxifenil)-ciclohexano-1,3-diol o 6-dimetilaminometil-1-(3-hidroxifenil)-ciclohexano-1,3-diol y un antiepileptico
BR112012028037A2 (pt) formulação de pró-emulsão líquida de taxano não aquosa, métodos para administrar um taxano a um paciente e para fabricar uma formulação de pró-emulsão de taxano, composição de emulsão de taxano, e, kit
CL2009000637A1 (es) Compuestos derivados sulfonamida sustituido, antagonista b1r; composición farmacéutica que los comprende; proceso de preparación de los compuestos, y uso en el tratamiento del dolor causado por inflamación, dolor agudo, neuropático, visceral, también en diabetes, migraña, entre otras.
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico

Legal Events

Date Code Title Description
FC Refusal